Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M Pharmaceutical Investing
Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse Pharmaceutical Investing
Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients Pharmaceutical Investing
Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding Pharmaceutical Investing
ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL Pharmaceutical Investing
Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2018 Pharmaceutical Investing
Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration Pharmaceutical Investing
Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB Biotech Investing
